The purpose of this study is to determine pharmacodynamic interactions of propofol and dexmedetomidine,exploring the effect of dexmedetomidine on propofol unconsciousness median effective concentration (EC50).
64 cases were randomly divided into four groups, In each group, dexmedetomidine target plasma concentration are 0, 0.4, 0.6, 0.8 ng/ml. Dexmedetomidine administered 15 min before target controlled infusion of propofol. The propofol infusion was started to provide a target effect-site concentration of 1.0ug/ml, and increased by 0.2ug/ml until loss of consciousness when the effect-site concentration and target concentration equilibrium.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
64
Dexmedetomidine target plasma concentration is 0.0ng/ml
Dexmedetomidine target plasma concentration is 0.4ng/ml
Dexmedetomidine target plasma concentration is 0.6ng/ml
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China
The EC50 of propofol for loss of consciousness
The aim of the investigators study is to define the optimum target concentration (EC50) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.
Time frame: within 30 min during the induction of anesthesia
The EC95 of propofol for loss of consciousness
The aim of the investigators study is to define the optimum target concentration (EC95) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.
Time frame: within 30 min during the induction of anesthesia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dexmedetomidine target plasma concentration is 0.8ng/ml